Pay in 4 interest-free payments of $6.17 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
There are several steps to follow when administering a subcutaneous injection
Heres what the clinical evidence shows: Study Scope: 900+ participants across 6 randomized, double-blind, placebo-controlled trials Safety Profile: Indistinguishable from placebo in tolerability assessments Serious Events: Zero serious adverse events attributed to AOD-9604 Withdrawals: No treatment-related discontinuations in any trial Common Effects: Mild headache and minor GI symptoms at rates similar to placebo IGF-1 Impact: No effect on insulin-like growth factor-1 levels Metabolic Safety: No negative impact on glucose metabolism or insulin sensitivity Immunogenicity: Zero participants developed anti-AOD9604 antibodies The following analysis provides complete details on the clinical trial evidence supporting AOD-9604s favorable safety profile
Both BPC-157 and TB-500 are unapproved investigational peptides
Regarding legal status, BPC-157 is not currently listed as a controlled substance under UK law
US$ 23.51
US$ 27.42
US$ 28.07
US$ 24.72
US$ 25.31
US$ 27.11
US$ 26.68
